Back HIV/AIDS

HIV / AIDS

CROI 2014: Boston Patients Experience HIV Rebound after Stem Cell Transplants

HIV has re-emerged in 2 Boston men who underwent experimental antiretroviral therapy (ART) interruption after receiving bone marrow stem cell transplants for cancer treatment, Timothy Henrich reported at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston. These cases suggest that a functional cure for HIV will be difficult to achieve if even a small amount of residual virus remains in the body.

alt

CROI 2014: HIV Rebounds in Boston Bone Marrow Transplant Patients [VIDEO]

Detectable HIV has returned in 2 Boston stem cell transplant recipients who for a time appeared to be controlling the virus during antiretroviral treatment interruption, Timothy Henrich from Brigham and Women's Hospital reported at the reported at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston.

alt

CROI 2014: Monkey Studies Confirm Validity of Injectable PrEP

Two studies in monkeys of an injectable formulation of the third-generation integrase inhibitor drug GSK1265744 (or GSK744LA, where LA stands for "long-acting") have strengthened the evidence that it may work as pre-exposure prophylaxis (PrEP) in humans, researchers reported at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston. A Phase 2 study in humans will be starting soon.

alt

CROI 2014: Protected T-cells Persist and Proliferate in HIV Gene Therapy Study

Genetically modified CD4 T-cells lacking CCR5 co-receptors reach high levels in the body and are resistant to HIV infection, potentially enabling people to maintain a low viral load while off antiretroviral therapy (ART), according to the latest reports from studies evaluating Sangamo Biosciences' SB-728-T zinc finger gene therapy technology.

alt

CROI 2014: Depression and HIV are Risk Factors for Heart Failure Among Veterans

Both HIV infection and depression are independent risk factors for incident heart failure, and living with both HIV and depression multiplies the risk, according to an analysis of data from the Veterans Aging Cohort Study presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston.

alt

CROI 2014: HIV Cure News from the Retrovirus Conference

The 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston featured updates related to various aspects of the search for a cure for HIV.

alt


CROI 2014: Tesamorelin Growth-Hormone Releaser Reduces Liver Fat in People with HIV

Tesamorelin, a synthetic form of growth-hormone-releasing hormone (GHRH), which the FDA has approved to reduce excess visceral abdominal fat in people living with HIV, also reduced associated liver fat in an HIV positive cohort chosen for abdominal adiposity, according to the results from a randomized, placebo-controlled trial presented at the 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014) this week in Boston.

alt